Literature DB >> 18667857

Inhibition of Escherichia coli O157:H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells.

Younghoon Kim1, Sae-Hun Kim, Kwang-Youn Whang, Young-Jun Kim, Sejong Oh.   

Abstract

The intestinal epithelial cell (IEC) layer of the intestinal tract makes direct contact with a number of microbiota communities, including bacteria known to have deleterious health effects. IECs possess innate protective strategies against pathogenic challenge, which primarily involve the formation of a physicochemical barrier. Intestinal tract mucins are principal components of the mucus layer on epithelial surfaces, and perform a protective function against microbial damage. However, little is currently known regarding the interactions between probiotics/pathogens and epithelial cell mucins. The principal objective of this study was to determine the effects of Lactobacillus on the upregulation of MUC2 mucin and the subsequent inhibition of E. coli O157:H7 attachment to epithelial cells. In the current study, the attachment of E. coli O157:H7 to HT-29 intestinal epithelial cells was inhibited significantly by L. acidophilus A4 and its cell extracts. It is also important to note that the expression of MUC2 mucin was increased as the result of the addition of L. acidophilus A4 cell extracts (10.0 mg/ml), which also induced a significant reduction in the degree to which E. coli O157:H7 attached to epithelial cells. In addition, the mRNA levels of IL-8, IL-1beta, and TNF-alpha in HT-29 cells were significantly induced by treatment with L. acidophilus A4 extracts. These results indicate that MUC2 mucin and cytokines are important regulatory factors in the immune systems of the gut, and that selected lactobacilli may be able to induce the upregulation of MUC2 mucin and specific cytokines, thereby inhibiting the attachment of E. coli O157:H7.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667857

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  37 in total

Review 1.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 2.  Probiotics in the next-generation sequencing era.

Authors:  Jotham Suez; Niv Zmora; Eran Elinav
Journal:  Gut Microbes       Date:  2019-04-05

3.  Lactobacillus jensenii surface-associated proteins inhibit Neisseria gonorrhoeae adherence to epithelial cells.

Authors:  Rachel R Spurbeck; Cindy Grove Arvidson
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

Review 4.  Biodiversity of Intestinal Lactic Acid Bacteria in the Healthy Population.

Authors:  Marika Mikelsaar; Epp Sepp; Jelena Štšepetova; Epp Songisepp; Reet Mändar
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Upregulation of Intestinal Mucin Expression by the Probiotic Bacterium E. coli Nissle 1917.

Authors:  Mohamed M Hafez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

6.  The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation.

Authors:  Tarun Bansal; Robert C Alaniz; Thomas K Wood; Arul Jayaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 7.  The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis.

Authors:  Michel J van Vliet; Hermie J M Harmsen; Eveline S J M de Bont; Wim J E Tissing
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

Review 8.  Role of probiotics in prevention and treatment of enteric infections: a comprehensive review.

Authors:  Zunaira Iqbal; Shahzaib Ahmed; Natasha Tabassum; Riya Bhattacharya; Debajyoti Bose
Journal:  3 Biotech       Date:  2021-04-27       Impact factor: 2.406

9.  Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.

Authors:  V R M Lombardi; E Martínez; R Chacón; I Etcheverría; R Cacabelos
Journal:  J Biomed Biotechnol       Date:  2009-07-06

10.  Treatment with the Probiotic Product Aviguard® Alleviates Inflammatory Responses during Campylobacter jejuni-Induced Acute Enterocolitis in Mice.

Authors:  Markus M Heimesaat; Dennis Weschka; Soraya Mousavi; Stefan Bereswill
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.